TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02844400

Intervention type: DEVICE
Intervention: Biometric Devices
Description: Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.

Intervention type: DEVICE
Intervention: Biometric Devices
Description: Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.

Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.

Intervention type: OTHER
Intervention: Physical Performance Testing
Description: Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
Study: NCT03335449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective ventilation group
Description: Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
Study: NCT04238858

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Platelet rich plasma
Description: blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
Study: NCT00324350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
Description: type 2 diabetes treatments, per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
Description: type 2 diabetes treatments, per standard of care
Study: NCT00309049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
Study: NCT03584724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norflo Oro
Description: Norflo Oro is highly bioavailable curcumin complexed into phytosomes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Norflo Oro
Description: Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
Study: NCT00664131

Intervention type: OTHER
Intervention: Neurological Examination/Questionnaires
Description: See Detailed Description section for description of treatment plan.
Study: NCT01478165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Total intravenous anesthesia
Description: Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia plus palonosetron
Description: Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
Study: NCT03914911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Biopsy Device
Description: The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
Study: NCT03466242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Evaluate sedative and analgesic effects of Intravenous Ketamine
Study: NCT00895947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha
Description: a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo lozenges for oral dissolution taken once daily for 16 weeks
Study: NCT03084367

Intervention type: DIAGNOSTIC_TEST
Intervention: iFR pullback
Description: iFR pullback assessment post angiographically successful PCI
Study: NCT02119819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02647905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Description: Accuracy and safety assessment of a continuous glucose monitoring device
Study: NCT02119819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Oral
Study: NCT03507023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolaid®
Description: 500 mg per day, in fasting conditions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg per day, in fasting conditions.
Study: NCT01762475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Study: NCT01190553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
Study: NCT04021849

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Face-to-face Class
Description: The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous Virtual Class
Description: Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
Study: NCT01315132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matched Sibling Allogeneic Transplantation
Description: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
Study: NCT01714232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® PLUS BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch® SelectSimple™ BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Performa BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Active BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Freedom® BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study: NCT03775759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid valve repair or replacement
Description: Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management of tricuspid regurgitation
Description: The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
Study: NCT02864810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GP1
Description: \[18F\]GP1 PET/CT imaging for detecting thromboembolism
Study: NCT03673657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early Nutrition Intervention from the start of CCRT
Description: Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly DP chemotherapy concurrent with thoracic radiotherapy
Description: Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
Study: NCT00635063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD 923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD 923
Study: NCT03913819

Intervention type: DRUG
Intervention: First line treatment: oral NSAID and anticholinergic agents
Description: oral NSAID and anticholinergic agents

Intervention type: DRUG
Intervention: Second line treatment: additional treatment for pain control
Description: Gabapentin, tramadol, Lyrica

Intervention type: DRUG
Intervention: Third line treatment: A course of intravesical hyaluronate will be given.
Description: A course of intravesical hyaluronate will be given.

Intervention type: PROCEDURE
Intervention: Fourth line treatment: surgical intervention
Description: Consideration of hydrodistention and augmentation cystoplasty
Study: NCT03090607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aluvra™
Description: Endoscopic injection of bulking agent to the lower esophageal sphincter

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Endoscopic injection of saline
Study: NCT01459562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00355810

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo followed by Lactobacillus plantarum MF 1298
Description: placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum MF1298 followed by placebo
Description: Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
Study: NCT02373033

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natural food folate
Description: Consumed folate-rich foods (providing additional 250 μg/d folate).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: Received a folic acid supplement (providing additional 500 μg/d folic acid).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple juice
Description: Received apple juice containing no folate or folic acid.
Study: NCT01064050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone trachea-bronchial stent Dumon (Novatech)
Description: Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
Study: NCT02185716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5%
Study: NCT00978263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin-based Oral Antidiabetic Drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Study: NCT02679235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POST Triheptanoin
Description: The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
Study: NCT04293796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy
Description: The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy
Description: The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
Study: NCT03368456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S4E
Description: S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs and a forthcoming module on tobacco prevention and cessation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
Study: NCT00935688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test
Description: Dual species test for P. vivax and P. falciparum malaria
Study: NCT00121134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Once a day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Twice daily for the first two days of every week for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
Study: NCT00715936

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Nutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Nutrition
Study: NCT01470768

Intervention type: OTHER
Group type: OTHER
Intervention: Amino Acid-based Formula with high DHA and ARA

Intervention type: OTHER
Group type: OTHER
Intervention: Amino Acid-based Formula with lower DHA and ARA
Study: NCT05748249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vertistop® D
Description: Vitamin D supplementation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vertistop® D
Description: Vitamin D supplementation
Study: NCT00742066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Single dose 600mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine
Description: single dose 10mg Felodipine ER
Study: NCT03554889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell adaptive transfer
Description: Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
Study: NCT00742066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose tablet orally
Study: NCT04325035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
Study: NCT02656511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir 50 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir
Description: Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
Study: NCT01399879

Intervention type: OTHER
Intervention: Faraday cage, movement stabilization
Description: The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
Study: NCT05532371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with lower limb strengthening
Description: The participants performed aerobic exercise training and lower limb strengthening during this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training combined with lower limb strengthening group (DG)
Description: The participants performed dual-task training combined with lower limb strengthening during this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training combined with dual-task training and lower limb strengthening
Description: The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
Study: NCT03554889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer